UNSPSC 51142567: Profenamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O00T1I1VRN, chemically known as 10h-phenothiazine-10-ethanamine, n,n-diethyl-.alpha.-methyl-, monohydrochloride but more generally known as ethopropazine hydrochloride, which bears US NIH Compound Identifier 3290. European Medicines Agency schedules Profenamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04056MIG.

Most nations, for tariff and trade purposes, schedule profenamine hydrochloride under HS 29343090. SMILES: CCN(CC)C(C)CN1C2CCCCC2SC3C1CCCC3.CL.

UNSPSC 51142567 Profenamine hydrochloride, a Commodity code, does not align with recent state and local procurement activity posted under this classification. The three recent opportunities tagged to this code solicited naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which match the specific pharmaceutical substance named in the code. The mismatch suggests either tagging error or that profenamine hydrochloride is rarely procured by state and local bodies, or when it is, not classified under this code number in practice. No concrete state and local demand for profenamine hydrochloride itself appears in the recent opportunity record.

The issuing bodies and geographic spread visible in these misaligned opportunities show activity by county health systems (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP, serving Oregon and other participating jurisdictions). The representative solicitations include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer pharmacy programs posted April 3, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Since these opportunities do not reflect genuine demand for profenamine hydrochloride, this code should be marked as showing no relevant recent activity for business development purposes.